Premium
Rhabdomyolysis caused by the moderate CYP 3A4 inhibitor fluconazole in a patient on stable atorvastatin therapy: a case report and literature review
Author(s) -
Hsiao S.H.,
Chang H.J.,
Hsieh T.H.,
Kao S.M.,
Yeh P.Y.,
Wu T.J.
Publication year - 2016
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12425
Subject(s) - rhabdomyolysis , atorvastatin , fluconazole , medicine , statin , drug , adverse effect , cyp3a4 , adverse drug reaction , pharmacology , antifungal , dermatology , cytochrome p450 , metabolism
Summary What is known and objective Rhabdomyolysis is a severe potential adverse drug reaction of statin therapy. We report a case of rhabdomyolysis due to drug–drug interaction ( DDI ) between atorvastatin and fluconazole and review the literature. Case summary A 70‐year‐old woman received atorvastatin for hyperlipidaemia without any problem for 4 years. When intravenous fluconazole was added for treating a fungal infection, rhabdomyolysis developed 2 weeks later. Removal of atorvastatin led to the resolution of her rhabdomyolysis. What is new and conclusion Our case demonstrates that in some subjects even a moderate CYP 3A4 inhibitor such as fluconazole may lead to rhabdomyolysis in subjects receiving a statin.